BlueCross BlueShield Of Michigan Reduces Antidepressant Trials Needed For Neuronetics TMS Access

Neuronetics, Inc., which designs and markets the NeuroStar transcranial magnetic stimulation device (TMS), announced a health care policy update from BlueCross BlueShield (BCBS) of Michigan that expands eligibility for TMS treatment for members with depression. The policy reduces the number of antidepressant medication attempts from four down to two prior to TMS treatment eligibility.

NeuroStar TMS is a non-drug treatment that can help alleviate the burden of drug-resistant depression. It is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients . . .